142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom

Subjects

Subjects :

Oncology
Immunology and Allergy

Details

ISSN :

25900188

Volume :

16

Database :

OpenAIRE

Journal :

Immuno-Oncology and Technology

Accession number :

edsair.doi...........5207252be16aa7d378655e63fb57aed4

Full Text :

https://doi.org/10.1016/j.iotech.2022.100254